De­cen­tral­ized tri­als com­pa­ny Sci­ence 37 to go pri­vate in deal with di­ag­nos­tics start­up eMed

Sci­ence 37, one of the star­tups that fu­eled the rise in de­cen­tral­ized clin­i­cal tri­als, will go pri­vate and see its one-time $1 bil­lion val­u­a­tion evap­o­rate to just a $38 mil­lion eq­ui­ty val­ue in an all-cash deal with eMed.

The tele­health and di­ag­nos­tics com­pa­ny eMed, which gained pop­u­lar­i­ty dur­ing the pan­dem­ic for its at-home Covid-19 test in 2020, will buy Sci­ence 37 for $5.75 per share in cash, the com­pa­nies said Mon­day morn­ing. The deal rep­re­sents a 21.3% pre­mi­um to Sci­ence 37’s Fri­day clos­ing price. The North Car­oli­na com­pa­ny’s shares $SNCE were up about 17% be­fore the open­ing bell.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER